Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

iRhythm CEO considers costs on the path to profitability

January 11, 2022 By Jim Hammerand

iRhythm's Zio cardiac monitoring device

iRhythm’s Zio cardiac monitoring device [Image courtesy of iRhythm]

Fresh off positive reimbursement news for its Zio remote external electrocardiogram monitoring device, the CEO of iRhythm Technologies (NSDQ:IRTC) doesn’t just have revenue on his mind.

iRhythm President and CEO Quentin Blackford — the former Dexcom COO who replaced Mike Coyle in September — said his company will need to keep costs under control as it grows to serve tens of millions and then hundreds of millions of patients in the years ahead.

“This means introducing things like automation where it’s possible, reconfiguring processes and streamlining systems and structures across the organization, as well as really rethinking how and where we do the work in this new remote environment that we’re proving can be so successful,” Blackford said today at the J.P. Morgan Healthcare Conference. “Ultimately our goal is to ensure that we have the infrastructure in place to ensure long-term profitable revenue growth.”

iRhythm CEO Quentin Blackford

iRhythm President and CEO Quentin Blackford [Photo courtesy of iRhythm]

Asked about the company’s path to profitability, Blackford said he feels “pretty good” about how much the company is spending on R&D, marketing and sales as a percentage of revenue, but flagged general and administrative (G&A) costs and back-office expenses as a “big gap for us.”

“The big challenge is the fact that we’ve got G&A spend that sits at well north of 50% of every revenue dollar, being consumed by back office and G&A-type activities,” he said. “That’s where we have to get focused to really drive the meaningful leverage into the future, coupled with our cost of sale, the COGS profile of the business. … Both of those areas have increased significantly over the last — call it two years or eight quarters — both on a unit cost perspective and a cost-to-serve perspective.”

Managing those costs will allow iRhythm to invest in innovation and growth, Blackford said. At the same time, some of the savings “gets dropped through to the bottom line and creates the nice financial leverage into the profile of the company into the future.”

“It’s about introducing this operational discipline and just really setting the company up for long-term scalable, profitable growth that affords you those sort of opportunities to invest in growth drivers,” he said.

Blackford also said he hopes for a final reimbursement rule and rate sometime in 2023.

iRhythm stock jumped about 40% after Monday’s positive news, and a BTIG research report projected shares to trade even higher in the quarters ahead.

“Despite the reimbursement uncertainty throughout 2021, [iRhythm] has consistently reported strong sequential volume growth and is working to reduce operating expenses, namely G&A,” BTIG analysts Marie Thibault and Sam Eiber wrote in the report. “The company continues to have several growth drivers, including continued demand for the core product Zio XT, recent traction with Zio AT, future market opportunities in silent AFib, and international expansion.”

With more than 1,600 employees (up from around 1,500 in late 2021), San Francisco-based iRhythm is one of the largest medtech companies in the world, ranking No. 97 on our 2021 Medtech Big 100.

You may also like:

  • iRhythm Zio XT on woman
    How iRhythm sought to outdo the old-school Holter monitor

Related Articles Read More >

Boston Scientific whistleblower launches corruption investigation
A portrait of Cathy Burzik, CEO of CFB Interests
5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
An automotive grill made by additive manufacturing, or 3D printing
Stratasys plans to buy Covestro’s additive manufacturing business
A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says

DeviceTalks Weekly.

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech